Since the value of Ki67 LI is more crucial for therapy decisions in G2-G3, ER positive/ HER2 negative breast cancers, a further analysis of consistency between VA and DIA of Ki67 LI in 91 cases of G2-G3, ER positive/ HER2 negative breast cancers were performed. This evidence concerns the gene ESR1 and breast carcinoma.